June 15, 2021

Download Ebook Free New Combination Approaches To Enhance Rituximab-based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies
Author : Anonim
Publisher : Academic Press
Release Date : 2020-11-01
Category : Business & Economics
Total pages :250
GET BOOK

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Yonsei Medical Journal

Yonsei Medical Journal
Author : Anonim
Publisher : Unknown
Release Date : 2007
Category : Medicine
Total pages :129
GET BOOK

Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy

Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
Author : Patrik Andersson,Christian Ostheimer
Publisher : Frontiers Media SA
Release Date : 2019-12-27
Category :
Total pages :129
GET BOOK

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.

Perry's The Chemotherapy Source Book

Perry's The Chemotherapy Source Book
Author : Michael C. Perry,Donald C. Doll,Carl E. Freter
Publisher : Lippincott Williams & Wilkins
Release Date : 2012-07-30
Category : Medical
Total pages :848
GET BOOK

Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Lymphoma: New Insights for the Healthcare Professional: 2012 Edition

Lymphoma: New Insights for the Healthcare Professional: 2012 Edition
Author : Anonim
Publisher : ScholarlyEditions
Release Date : 2012-12-10
Category : Medical
Total pages :255
GET BOOK

Lymphoma: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Lymphoma. The editors have built Lymphoma: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lymphoma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Lymphoma: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality

Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality
Author : Abhishek D Garg,Patrizia Agostinis
Publisher : Frontiers Media SA
Release Date : 2016-04-29
Category :
Total pages :129
GET BOOK

Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.

Clinical Radiation Oncology

Clinical Radiation Oncology
Author : Leonard L. Gunderson,Joel E. Tepper
Publisher : Elsevier Health Sciences
Release Date : 2007
Category : Medical
Total pages :1827
GET BOOK

First Prize winner, Oncology Book Category, British Medical Association 2012 Medical Book Competition Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors -many of whom are new to this edition - affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines. Drs. Gunderson and Tepper give you quick access to all the clinical tools you need to master the newest techniques and modalities in radiation oncology.

The Journal of Immunology

The Journal of Immunology
Author : Anonim
Publisher : Unknown
Release Date : 2007
Category : Immunology
Total pages :129
GET BOOK

Annual Meeting Proceedings

Annual Meeting Proceedings
Author : American Society of Clinical Oncology. Meeting
Publisher : Unknown
Release Date : 2007
Category :
Total pages :129
GET BOOK

40th Annual Meeting of the American Society of Clinical Oncology

40th Annual Meeting of the American Society of Clinical Oncology
Author : American Society of Clinical Oncology. Annual Meeting,American Society of Clinical Oncology
Publisher : Unknown
Release Date : 2004
Category : Cancer
Total pages :1064
GET BOOK

Dissertation Abstracts International

Dissertation Abstracts International
Author : Anonim
Publisher : Unknown
Release Date : 2008
Category : Dissertations, Academic
Total pages :129
GET BOOK

Journal of the National Cancer Institute

Journal of the National Cancer Institute
Author : Anonim
Publisher : Unknown
Release Date : 2002
Category : Cancer
Total pages :129
GET BOOK

"Summaries of papers" contained in the journal accompany each issue, 19--

CpG Vaccine Strategies Induce Tumor-reactive T Cells for Adoptive Therapy of Lymphoma

CpG Vaccine Strategies Induce Tumor-reactive T Cells for Adoptive Therapy of Lymphoma
Author : Matthew Jordan Goldstein
Publisher : Unknown
Release Date : 2010
Category :
Total pages :129
GET BOOK

Despite the success of passive immunotherapy with monoclonal antibodies (mAb) directed against tumor cells (e.g. anti-CD20, rituximab), many lymphoma patients eventually relapse. Active immunotherapy for the treatment of lymphoma aims to induce an adaptive and long-lasting antitumor immune response to prevent or prolong time to recurrence. Although antitumor immune cells can be found in cancer patients, these cells may be rendered ineffective in eradicating cancer due to tumor-induced immunosuppression. One approach to overcome this--adoptive cell therapy--involves the isolation of tumor-specific T cells followed by their re-administration to a patient after a myeloablative conditioning regimen. The work discussed in this dissertation describes our studies on a novel approach to adoptive cell therapy for lymphoma. Specifically, we have investigated vaccination methods for generating tumor-reactive T cells in vivo and demonstrate a strategy to isolate this specific population. Prior work from our lab has shown that a combination of chemotherapy (CTX) plus intra-tumor injection of CpG cures a majority of tumors in the A20 mouse B cell lymphoma model. In these studies we found that it was necessary to inject CpG directly into the tumor. We concluded that CpG can have an immunostimulatory effect on either the tumor B cell or on the host APC to enhance uptake and presentation of tumor antigens thereby leading to a cytotoxic CD8 antitumor T cell response. We posited that the effectiveness of the CTX + CpG vaccination maneuver may be limited by endogenous regulatory factors of the immune system. Myeloablation eliminates many of these factors and creates an environment that is conducive to the adoptive transfer of anti-tumor lymphocytes. Transferred cells respond to homeostatic proliferation signals and repopulate 'empty' lymphocyte niches. We utilized CTX + CpG active immunization to generate anti-tumor T cells in vivo and transferred these T cells into lymphodepleted recipient mice. We refer to the preparation of these cells and subsequent transfer as 'immunotransplant'. Transferred T cells cured large and metastatic tumors. We demonstrated that tumor rejection was mediated by donor CD8 T cells. These transferred tumor-specific Teffector cells preferentially expanded, increasing the Teffector:Treg ratio in recipients. This work demonstrates that in situ vaccination is an efficient and effective means to generate T cells for adoptive therapy. The second phase of our work focused on designing an alternative strategy for generating antitumor T cells in vivo. We designed a CpG-loaded tumor cell vaccine made up of irradiated-tumor cells (a rich source of tumor antigens) loaded with CpG. The T cells induced by this vaccine could mediate antitumor immune responses and were more effective when adoptively transferred into lymphodepleted mice. CpG-loaded tumor cells were phagocytosed delivering both tumor antigen and the immunostimulatory CpG molecule to APCs. These APCs then expressed increased levels of costimulatory molecules and induced T cell immunity. TLR9 was required in the APC but not in the CpG-loaded tumor cell. We demonstrate that T cells induced by this vaccine were effective in adoptive cellular therapy for lymphoma and led to regression of large and established tumors. Interestingly, this therapeutic effect could be transferred by CD4 but not by CD8 T cells. This CpG-loaded whole cell vaccination has strong potential for translation to the clinical setting. We were surprised that our CpG-loaded tumor cell vaccine induced an antitumor CD4 T cell response. To date, the field of adoptive cell therapy has focused primarily on CD8 CTLs and our early work with CTX + CpG vaccination supported this paradigm. However, the concept of CD4 T cells coordinating broad, antitumor responses is important for the field of adoptive therapy. CD4 cells play central roles in nearly all aspects of the adaptive immune response including the recruitment of other immune cell types as well as the activation of B cells and APCs. However, clinical translation of using CD4 T cells for adoptive therapy is limited by potential to co-transfer regulatory CD4 T cells (Tregs). In the third phase of our work, we identified a method for isolating viable antitumor CD4 T cells while excluding Tregs based on two surface markers--CD44 and CD137. Adoptive transfer of CD137negCD44hi CD4 T cells, but not other sub-populations, provided protection from B cell lymphoma. We demonstrate that the population of CD137posCD44hi CD4 T cells consists primarily of activated Tregs. In vitro, these CD137pos cells suppressed the proliferation of effector cells in a contact-dependent manner. Moreover, in vivo the addition of CD137posCD44hi CD4 cells to CD137negCD44hi CD4 cells suppressed the antitumor immune response. These results suggest that CD137 expression on CD4 T cells defines a population of activated Tregs that prevent antitumor immune responses. Similar to observations in the murine model, human lymphoma biopsies also contain a population of CD137pos CD4 T cells that are predominantly CD25posFoxP3pos Tregs. In conclusion, our findings identify two surface markers that can be used to facilitate the enrichment of anti-tumor CD4 T cells while depleting an inhibitory Treg population. Together, these findings define a T cell-based therapy for lymphoma. We have established two methods of vaccination that are effective in generating antitumor T cells and show that these cells can reject established and metastatic tumors. T cell responses differ based on the route of vaccination, however we show that both vaccine-induced CD4 and CD8 T cells can mediate tumor rejection. Finally, we have described two surface molecules that could facilitate isolation of tumor-reactive CD4 T cells while removing tumor-reactive regulatory T cells. This work has direct implications for clinical therapy and a proof-of-concept clinical trial of adoptive immunotherapy for mantle cell lymphoma is ongoing.

Cancer Research

Cancer Research
Author : Anonim
Publisher : Unknown
Release Date : 2009-12
Category : Cancer
Total pages :129
GET BOOK

Melmon and Morrelli's Clinical Pharmacology

Melmon and Morrelli's Clinical Pharmacology
Author : Kenneth L. Melmon,Howard F. Morrelli,David F. Nierenberg
Publisher : McGraw Hill Professional
Release Date : 2000
Category : Medical
Total pages :1433
GET BOOK

Perfect for the student, primary care practitioner, and pharmacist who needs both basic and clinical information to apply therapeutics A new overview chapter--plus practical steps required for optimal therapeutic decisions Coverage of newly emerging advances in therapeutics A new look at cost/benefit analysis of therapy Increased emphasis on drug interactions, and much more